Levodopa-induced response fluctuations in patients with Parkinson's disease: Strategies for management

CNS Drugs

Volumn 17, Issue 7, 2003, Pages 475-489

  Van Laar, Teus ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PRODRUG; ROPINIROLE;

BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DYSTONIA; ENZYME INHIBITION; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SLOW RELEASE FORMULATION; STEREOTAXIC SURGERY; SUBCUTANEOUS NODULE;

AGE FACTORS; ANTIPARKINSON AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEVODOPA; MOTOR ACTIVITY; MOVEMENT DISORDERS; PARKINSON DISEASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037606200     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317070-00002     Document Type: Review

References (89)

1. Morrish PK, Sawle GV, Brooks DJ. The rate of progression of Parkinson's disease: a longitudinal [18F]DOPA PET study. In: Battistin L, Scarlato G, Caraceni T, et al., editors. Advances in neurology. Vol. 69. Philadelphia (PA): Lippincott-Raven Publishers, 1996: 427-31
2. Leenders KL. Pathophysiology of movement disorders studied using PET. J Neural Transm Suppl 1997; 50: 39-46
3. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of the clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4
4. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; I: 345-9
5. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled-release carbidopa/levodopa in PD: a multicenter 5-year study. Eur Neurol 1997; 37: 23-7
6. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 1991; 41: 168-73
7. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community based study. Brain 2000; 123: 2297-305
8. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific, 1982: 123-45
9. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561-73
10. Melamed E, Bitton V, Zelig O. Delayed onset of response to single doses of L-dopa therapy. Clin Neuropharmacol 1986; 9: 182-8
11. Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 1986: 36: 100-3
12. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific, 1982: 96-122
13. Lees AJ, Shaw KM, Stern GM. Off-period dystonia and on-period choreoathetosis in levodopa-treated Parkinson's disease [letter]. Lancet 1977; 11: 1034
14. Muenter MD, Sharpless NS, Tyce GM, et al. Patterns of dystonia in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977; 52: 163-74
15. Melamed E. Early-morning dystonia: a late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 1979; 36: 308-10
16. Nausieda PA, Weiner WJ, Klawans HL. Dystonic foot response of parkinsonism. Arch Neurol 1980; 37: 132-6
17. Curtis L, Lees AJ, Stern GM, et al. Effect of L-dopa on course of Parkinson's disease. Lancet 1984; II: 211-2
18. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23: 73-8
19. Nutt JG, Woodward WR, Carter JH, et al. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989; 52: 481-7
20. Baruzzi A, Cantin M, Riva R. Influence of meal ingestion time on pharmacokinetics of orally-administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987; 10: 527-37
21. Carter JH, Nutt JH, Woodward WR. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 1990; 39: 401-4
22. Kurth MC, Tetrud LW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology 1993; 43: 1036-9
23. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987; 21: 370-6
24. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Pt I. Ann Neurol 1988; 24: 366-71
25. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central and pathophysiological mechanisms. Pt II. Ann Neurol 1988; 24: 372-8
26. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with PET. J Neurol Neurosurg Psychiatry 1986; 49: 853-60
27. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36: 27-31
28. Kostic V, Przedborski S, Flaster E, et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41: 202-5
29. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Which risk factors predict the levodopa response in fluctuating Parkinson's disease. Ann Neurol 1990; 27: 537-43
30. De Jong GJ, Meerwaldt JD, Schmitz PIM. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987; 22: 4-7
31. Roos RAC, Vredevoogd CB, Van der Velde EA. Response fluctuations in Parkinson's disease. Neurology 1990; 40: 1344-6
32. Montastruc JL, Rascol O, Senard JM, et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-8
33. Vermeulen RJ, Drukarch B, Sahadat MCR, et al. The selective dopamine D1 receptor agonist SKF 81297, stimulates motor behavior of MPTP-lesioned monkeys. Eur J Pharmacol 1993; 235: 143-7
34. Vermeulen RJ, Drukarch B, Sahadat MCR, et al. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disorder 1994; 9: 664-72
35. Grondin R, Bédard PJ, Britton DR, et al. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 1997; 49: 412-26
36. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Levodopa. Mov Disord 2002; 17 Suppl. 4: S23-37
37. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. DA agonists non-ergot derivatives: apomorphine. Mov Disord 2002; 17 Suppl. 4: S83-9
38. Lledo A. Dopamine agonists: the treatment for Parkinson's disease in the XXI century? Parkinsonism Relat Disord 2001; 7: 51-8
39. Bedard PJ, Di Paolo T, Falardeau P, et al. Chronic treatment with L-dopa, but not bromocriptine, induces dyskinesia in MPTP-parkinsonian monkeys. Brain Res 1986; 379: 294-9
40. Pearce RK, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998; 13: 234-41
41. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000; 23 Suppl. 10: S8-S19
42. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-81
43. Wolters EC, Tissingh G, Bergmans PLM, et al. Dopamine agonists in Parkinson's disease. Neurology 1995; 45 Suppl. 3: S28-34
44. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996; 5 (5): 369-88
45. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997; 20 (2): 95-115
46. Olanow CW, Watts RL, Koller WC. An algorithm for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56 Suppl. 5: S1-S88
47. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, et al. A six-month study of pergolide and L-dopa in de novo Parkinson's disease patients. Clin Neuropharmacol 1998; 21: 358-62
48. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997; 49 (1 Suppl. 1): S34-48
49. Clarke CE. Dopamine agonist therapy in advanced Parkinson's disease. Neurology Rev Int 1998; 2: 1-5
50. Boas J, Worm-Petersen J, Dupont J, et al. The levodopa dose-sparing capacity of pergolide compared to that of bromocriptine in an open-label, cross-over study. Eur J Neurol 1996; 3: 44-9
51. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9 (1): 40-7
52. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33 (8): 1009-14
53. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9 (4): 431-6
54. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report: Parkinson's Disease Research Group in the United Kingdom. BMJ 1993; 307 (6902): 469-72
55. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57 (8): 903-10
56. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000; 342: 1484-91
57. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study: Pergolide Monotherapy Study Group. Neurology 1999; 53: 573-9
58. Parkinson Study Group G. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931-8
59. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Drugs 1998; 55 Suppl. 1: S23-30
60. Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986; 9: 430-9
61. Coleman RJ. Current drug therapy for Parkinson's disease. Drugs Aging 1992; 2 (2): 112-24
62. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord 2002; 17 Suppl. 4: S38-44
63. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations. Neurology 1997; 48: 81-7
64. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-55
65. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309-14
66. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996; 60: 36-40
67. Nutt JG. Effects of COMT inhibition on the pharmacokinetics of L-dopa. Adv Neurol 1996; 69: 493-6
68. Lyytinen J, Kaakkola S, Ahtila S, et al. Simultaneous MAO-B and COMT inhibition in L-dopa treated patients with Parkinson's disease. Mov Disord 1997; 12: 497-505
69. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 1993; 7: 121-8
70. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994; 17: 243-59
71. van Laar T, Jansen ENH, Essink AWG, et al. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992; 49: 482-4
72. Dewey RB, Maraganore DM, Ahlskog JE. A double-blind placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov Disord 1998; 13: 782-7
73. Merello M, Pikielny R, Cammarota A, et al. Comparison of subcutaneous apomorphine versus dispersible Madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol 1997; 20: 165-7
74. Nutt JG, Carter JH, Lea ES, et al. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997; 12: 285-92
75. Melamed E, Zoldan J, Galili-Mosberg R, et al. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. J Neural Transm Suppl 1999; 56: 173-83
76. Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996; 39: 401-4
77. Gancher GT, Nutt JG, Woodward WR. Time course of tolerance to apomorphine in Parkinsonism. Clin Pharmacol Ther 1992; 52: 504-10
78. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999; 37: 257-71
79. Stocchi F, Farina C, Nordera G, et al. Implantable venous access system for apomorphine infusion in complicated Parkinson's disease [letter]. Mov Disord 1999; 14: 358
80. Verhagen Metman L, Van den Munckhof P, Klaassen AAG, et al. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 1997; 49: 711-3
81. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996: 39: 574-57
82. Verhagen Metman L, Del Dotto P, Van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-6
83. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56: 1383-6
84. Uitti Rj, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of survival in Parkinson's disease. Neurology 1996; 46: 1551-6
85. Bennett JP, Elke R, Landow RN, et al. Suppression of dyskinesias in advanced Parkinson's disease. Neurology 1993; 43: 1551-5
86. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998; 13: 377-82
87. Durif F, Vidailhet M, Assal F, et al. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997; 48: 658-62
88. Deuschl G, Krack P, Volkmann J. Deep brain stimulation for movement disorders. Mov Disord 2002; 7 Suppl. 3: S1-211
89. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998; 55 Suppl. 1: 1-9